Category: JCN Newswire

ISTANBUL, Turkiye, August 1, 2025 - (JCN Newswire via SeaPRwire.com) – Honda Turkiye A.S. (HTR) has decided to establish a new motorcycle factory in Aliaga, izmir, aimed at supporting growth in the motorcycle market and boosting global motorcycle sales.The COVID-19 pandemic has led to an increased demand for personal transportation and commercial use, such as delivery services, driving significant growth in the Turkish motorcycle market. As a result, Honda Turkiye set a new sales record in 2024 with annual sales reaching 162,000 motorcycles.Production is scheduled to begin in mid-2026. Initially, the plant will operate with an annual capacity of 100,000 motorcycles, with plans to increase production capacity to 200,000 units in the future. The total investment amount for the facility including machinery and equipment is approximately 20 million USD. The plant is expected to create employment opportunities for around 300 people.With this new investment, Honda Turkiye aims to strengthen local production activities and contribute to the development of the motorcycle industry in Turkiye by providing high-quality, affordable, and attractive products. About Honda Turkiye A.S.Established :February 1992Headquarter :Maltepe, IstanbulCapital :180 million TLOwnership :Honda Motor Europe Ltd. (100%)President :Satoru YamadaBusiness Activities :Import and sales of motorcycles, automobiles, and partsNumber of Employees :Approximately 160 (as of July 2025) Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Japan, August 1, 2025 - (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. (Honda) has started a demonstration project jointly with Tokuyama Corporation (Tokuyama) and Mitsubishi Corporation (MC), to operate a data center using by-product hydrogen and a stationary fuel cell (FC) power station designed to reuse FC systems from fuel cell electric vehicles (FCEVs). The companies today held an opening ceremony at the demonstration site located in Shunan City, Yamaguchi Prefecture, Japan. Honda FC power station to be used for this demonstration projectThe three companies have been discussing and preparing for the launch of the demonstration project since June 2023, when this project was proposed to and adopted by the New Energy and Industrial Technology Development Organization (NEDO) as one of the projects for the “Development of Technologies for Realizing a Hydrogen Society / Development of Technologies for Regional Hydrogen Utilization.”In this demonstration project, a stationary FC power station that Honda has developed based on the assumption of reusing fuel cells recovered from FCEVs utilizes by-product hydrogen produced by Tokuyama’s salt water electrolysis business to generate electricity and supply the electricity to a distributed data center operated by MC, at the demonstration site located in Shunan City, Yamaguchi Prefecture, Japan.Through this demonstration project, the three companies will explore the potential of reusing automotive FC systems for stationary FC power station applications, and verify the possibility of contributing to 1) a reduction in the economic burden on customers who will install and operate stationary FC power stations and 2) the decarbonization of electric power, through effective use of FC systems, which are expected to see broader adoption in the future.A further increase in power demand for data centers is expected in the long run due to the advancement of technologies that require large-volume data processing, such as generative AI and automated driving. In the face of this market environment, by utilizing 1) by-product hydrogen, which can be produced/supplied stably with low carbon emissions, and 2) FCs designed to be reused, to supply electricity to distributed data centers, the three companies will strive to contribute to the “green transformation” (GX) of data centers and the digital transformation (DX) of municipalities and local businesses. Multiple patterns of power supply operations to be demonstratedIn this demonstration, electricity from multiple sources, such as 1) a stationary FC power station that utilizes by-product hydrogen, 2) the power grid, 3) stationary batteries (BESS*¹), and 4) renewable energy sources will be combined to verify more efficient and optimal power configuration for different patterns of operation.The following specific patterns of stationary FC power station utilization, based on various possible scenarios, will be demonstrated by switching among these operation patterns via an Energy Management System (EMS):1) Use as a backup power source2) Use as an off-grid primary power s1ource3) Use for peak shaving of grid electricity consumption4) Use for grid supply-demand balancing, including supplying electricity back to the gridIn addition to verifying the practicality and business viability of stationary FC power station operation, a wide range of potential applications will be explored through this demonstration project. *1 BESS: Battery Energy Storage System*2 Peak shaving: Reducing electricity consumption during peak demand periodsAbout Honda Stationary Fuel Cell Power StationHonda was one of the first companies to focus on the potential of hydrogen toward the realization of a carbon-neutral society and has been conducting research and development of hydrogen technologies and FCEVs for more than 30 years. Working toward the realization of carbon neutrality for all products and corporate activities Honda is involved in by 2050, Honda has identified four core domains for its fuel cell system application – fuel cell electric vehicles (FCEVs), commercial vehicles, stationary power station and construction machinery – and has been working to further expand opportunities for its hydrogen business.The Honda stationary FC power station is a stationary power storage system designed to supply clean, hydrogen-derived electricity to large-scale facilities such as factories and other business operations. The stationary FC power station being used in this demonstration project utilizes fuel cells used for a Honda CR-V e:FCEV fuel cell electric vehicle.The Honda stationary FC power station is capable of supplying electricity to meet the maximum amount of electricity consumption by the customer in accordance with their needs. Moreover, the compact size of the unit achieved by the optimization of the cooling system and internal layout enables flexible installation options to accommodate the conditions of the customer’s installation site. In addition, the Honda stationary FC power station is designed to achieve high responsiveness, aiming to begin power supply within 10 seconds of startup, to serve as a reliable backup power source in case of an emergency.Through its stationary FC power station, Honda will supply electricity that accommodates the various power needs of customers, while also contributing to the decarbonization efforts of each customer by providing comprehensive support for the entire process—from installation to after-sales services. For more details, please visit:https://global.honda/content/dam/site/global-en/newsroom-new/cq_img/news/2025/08/c250801aeng/c250801aeng.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.

KARIYA, JAPAN, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - BluE Nexus Corporation (headquartered in Anjo, Aichi; Hidetoshi Uchiyama, president; hereinafter “BluE”), AISIN Corporation (headquartered in Kariya, Aichi; Moritaka Yoshida, president; hereinafter “AISIN”), and DENSO CORPORATION (headquartered in Kariya, Aichi; Shinnosuke Hayashi, president; hereinafter “DENSO”) are proud to announce that, the eAxle jointly developed by the three companies has been installed in Isuzu's first battery electric vehicle (BEV) pickup, D-MAX EV, which went into production in April 2025.The newly installed product combines the newly developed eAxle front and rear with a full-time *4WD system, contributing to both the tough basic performance required for pickup trucks (durability/loading and towing performance/rugged road drivability) and the linear acceleration and low noise and vibration characteristic of BEVs. The BEV is a 4WD system with a low-noise and low-vibration engine.As D-MAX EVs are gradually expanded globally, starting with shipments to major European countries and gradually adapting to market characteristics and customer needs, this product will also provide high-performance drive solutions around the world.Going forward, BluE, AISIN, and DENSO will continue to provide valuable technologies and products by leveraging their respective strengths and know-how. In addition, through BluE, we will contribute to the realization of a carbon-neutral society by having our products installed in all types of electric vehicles.*Full-time 4WD is a drive system that transmits power to both the front and rear wheels at all times, regardless of road conditions, including off-road and on-road driving.About BluE Nexus,“BluE”BluE is an electrification system and electric drive module development and sales company established in April 2019. BluE aims to meet the needs of customers worldwide and contribute to the further development and popularization of electrified vehicles and the realization of carbon neutrality in society.About DENSO CORPORATIONGlobally headquartered in Kariya, Japan, DENSO is a 7,161.8 billion yen leading mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in around 180 facilities worldwide to provide opportunities for rewarding careers and to produce cutting-edge electrification, powertrain, thermal and mobility electronics products, among others, that change how the world moves. In developing such solutions, the company’s 158,000 global employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. DENSO spent around 8.6 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2025. For more information about DENSO’s operations worldwide, visit https://www.denso.com/global Copyright 2025 JCN Newswire via SeaPRwire.com.

Kawasaki, Japan, August 1, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced that it has started research and development towards a superconducting quantum computer with a capacity exceeding 10,000 qubits. Construction is slated for completion in fiscal 2030.The new superconducting quantum computer will operate with 250 logical qubits and will utilize Fujitsu's innovative "STAR architecture," an early-stage fault-tolerant quantum computing (early-FTQC) architecture also developed by the company. Fujitsu aims to make practical quantum computing possible, particularly in areas like materials science where complex simulations can unlock ground breaking discoveries, and to this end will focus on advancing key scaling technologies across various technical domains.As part of this effort, Fujitsu has been selected as an implementing party for the "Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems" [1], publicly solicited by the NEDO (New Energy and Industrial Technology Development Organization). Fujitsu will be contributing to the thematic area of advancing the development of quantum computers towards industrialization. The project will be promoted through joint research with Japan’s National Institute of Advanced Industrial Science and Technology (AIST) and RIKEN, and will run until fiscal year 2027.Fujitsu is committed to driving forward the development of practical and industrialized quantum computing solutions. After this 10,000-qubit machine is built, Fujitsu will further pursue advanced research initiatives targeting the integration of superconducting and diamond spin-based qubits from fiscal 2030 and aims to realize a 1,000 logical qubit machine in fiscal 2035 while considering the possibility of multiple interconnected quantum bit-chips.Vivek Mahajan, Corporate Executive Officer, Corporate Vice President, CTO, in charge of System Platform, Fujitsu Limited, comments:"Fujitsu is already recognized as a world leader in quantum computing across a broad spectrum, from software to hardware. This project, led by NEDO, will contribute significantly to Fujitsu’s goal of further developing a Made-in-Japan fault tolerant superconducting quantum computer. We would also be aiming to combine superconducting quantum computing with diamond spin technology as part of our roadmap. By realizing 250 logical qubits in fiscal 2030 and 1,000 logical qubits in fiscal 2035, Fujitsu is committed to leading the path forward globally in the field of quantum computing. Additionally, Fujitsu will be developing the next generation of its HPC platform, using its FUJITSU-MONAKA processor line, which will also power FugakuNEXT. Fujitsu will further integrate its platforms for high-performance and quantum computing to offer a comprehensive computing platform to our customers."Technology development focus areasFujitsu’s research efforts will focus on developing the following scaling technologies.1. High-throughput, high-precision qubit manufacturing technology:Improvement of the manufacturing precision of Josephson Junctions, critical components of superconducting qubits which minimize frequency variations.2. Chip-to-chip interconnect technology:Development of wiring and packaging technologies to enable the interconnection of multiple qubit chips, facilitating the creation of larger quantum processors.3. High-density packaging and low-cost qubit control:Addressing the challenges associated with cryogenic cooling and control systems, including the development of techniques to reduce component count and heat dissipation.4. Decoding technology for quantum error correction:Development of algorithms and system designs for decoding measurement data and correcting errors in quantum computations.BackgroundThe world faces increasingly complex challenges that demand computational power beyond the reach of traditional computers. Quantum computers offer the promise of tackling these previously intractable problems, driving significant advancements across numerous fields. While a fully fault-tolerant quantum computer with 1 million qubits of processing power is considered the ultimate goal, Fujitsu is focused on delivering practical solutions in the near term.Fujitsu's commitment to quantum computing is underscored by its ongoing R&D efforts. In August 2024, in collaboration with the University of Osaka, Fujitsu unveiled its STAR architecture, a highly efficient quantum computing architecture based on phase rotation gates. This architecture paves the way for early-FTQC systems capable of outperforming conventional computers with only 60,000 qubits [2]. On the hardware front, the RIKEN RQC-Fujitsu Collaboration Center, established in 2021 with RIKEN, has already yielded a 64-qubit superconducting quantum computer in October 2023, followed by a world-leading 256-qubit system in April 2025 [3].Scaling to even larger systems requires overcoming challenges such as maintaining high fidelity across multiple interconnected qubit chips and achieving greater integration of components and wiring within dilution refrigerators. In addition to its superconducting approach, Fujitsu is also exploring the potential of diamond spin-based qubits, which use light for qubit connectivity. Fujitsu is conducting research in this area in collaboration with Delft University of Technology and QuTech, a leading quantum technology research institute, which has resulted in the successful creation of highly accurate and controllable qubits.[1] Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems[2] In simulations using 60,000 qubits, the STAR architecture can execute material energy estimation calculations which would take 5 years on conventional computers in about 10 hours.[3] One of the world's largest superconducting quantum computers available to external users (as of April 2025, according to Fujitsu).About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue(pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 – June 30, 2025). By major markets, revenue came to JPY 9.1 billion in the United States, JPY 5.5 billion in Japan, and JPY 7.7 billion in Chinadue to increasing demand and stock piling by distributors (estimated at JPY 5.3 billion) in response to the risk of tariffs. This information is being disclosed in conjunction with today's announcement of the financial results for the second quarter of 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai’s financial results for the first quarter of fiscal year 2025, including details of LEQEMBI’s revenue, will be disclosed in Eisai's financial disclosure scheduled for August 5, 2025.Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority. Copyright 2025 JCN Newswire via SeaPRwire.com.

Takamatsu, Kagawa, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Sharp reached an agreement with Aoi Electronics Co., Ltd. (Headquarters / Takamatsu City, Kagawa Prefecture, President & CEO / Kazuhiro Kinoshita; hereinafter "Aoi Electronics") on the transfer of Sharp Mie Plant No.2 and part of the land at Sharp Mie Base.Under its asset-light initiative in devices business and to transfer its structure centering its Brand business, Sharp is promoting the utilization of underutilized and unused factories, as well as business development through collaboration with other companies. This agreement is part of such initiative and corresponds to the consideration of transferring the Mie Plant No.2 mentioned in the news release dated March 31, 2025.Through Sharp Display Technology Corporation, Sharp’s subsidiary in charge of small and medium size LCD business, Sharp will collaborate with Aoi Electronics on the early start-up of their production line in the factories they bought.*Property for Transfer(1) Sharp Mie Plant No. 2 (Building)・Location: Gosana, Taki-cho, Taki-gun, Mie Prefecture・Total Floor Area: Approx. 54,000 square meters (including production area: approx. 20,000 square meters)・Contract Date/ Delivery Date: July 31, 2025(2) Land ・Location: Gosana, Taki-cho, Taki-gun, Mie Prefecture・Land Area: Approx. 58,000 square meters (Land for Sharp Mie Plant No.1 and No.2)・Contract Date: July 31, 2025・Delivery Date: End of December, 2025 (plan) Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) has decided to enter into a business partnership with JEPLAN, INC. (Headquarters: Kawasaki City, Kanagawa; Representative Director, President, and Chief Executive Officer: Masaki Takao; hereinafter “JEPLAN”) to reduce CO₂ emissions and promote the recycling organic materials in the precious metal recovery processes of TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., a company engaged in precious metals business.This initiative represents a collaboration between TANAKA, committed to advancing a circular economy in the precious metals field, and JEPLAN, which has been pursuing similar goals in the plastics field, with both companies aiming to achieve a decarbonized, circular society.TANAKA’s Initiatives Thus Far for Realizing a Circular SocietySince its founding in 1885, TANAKA has been a leader in the precious metals industry, actively engaged in recycling these limited and valuable resources. Among the process waste materials received from customers who request recycling, those containing organic materials (plastics) as main components with precious metals attached or adsorbed have traditionally been processed through incineration to remove the organic materials, with precious metals then recovered from the ash left behind.While this incineration process has addressed the removal of environmentally regulated substances, the reduction of CO₂ generated during the combustion of organic materials has become a major challenge in realizing a decarbonized society.Transforming the Precious Metal Recovery Process Through a Business Partnership with JEPLANJEPLAN has established proprietary chemical recycling technology for polyethylene terephthalate, a type of plastic. To address the aforementioned CO₂ emissions issue, TANAKA is considering using chemical recycling in the future, in addition to the conventional precious metal recovery process through incineration. This initiative is being explored through a business partnership with JEPLAN. The materials targeted for chemical processing include plastics such as syringes and wiping cloths. CO₂ emissions from the targeted precious metal recovery process are expected to be reduced to approximately 10% of conventional levels.In addition, this process enables not only precious metal recovery, but also plastic regeneration, with TANAKA and JEPLAN each contributing to the realization of a decarbonized, circular society through their respective areas of expertise.JEPLAN, INC. ( https://www.jeplan.co.jp/en/ )Representative: Masaki Takao, Representative Director, President, and Chief Executive OfficerEstablished: January 2007Main Business: Business based and related to PET chemical recycling technology (for PET bottles, polyester), etc.The JEPLAN Group aims to realize a circular economy with its mission of "We circulate our world." We use our proprietary PET chemical recycling technology to break down waste PET (PET bottles, polyester fibers, etc.) into molecules and remove impurities, regenerating it into recycled materials of the same quality as petroleum-derived materials. Through our recycling efforts using this proprietary technology, we are realizing the recycling of limited resources and contributing to the reduction of CO₂ emissions.The JEPLAN Group operates PET chemical recycling plants at two locations, PET REFINE TECHNOLOGY CO., LTD. (Kawasaki City, Kanagawa Prefecture, for PET bottles) and Kitakyushu Hibikinada Plant (Kitakyushu City, Fukuoka Prefecture, for polyester fibers), and is also promoting technology licensing in Japan and overseas.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ending December 2024, was 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press release: https://www.acnnewswire.com/docs/files/20250731.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.

KARIYA, JAPAN, July 31, 2024 - (JCN Newswire via SeaPRwire.com) - DENSO, a leading mobility supplier, today announced global financial results for the first quarter, ending June 30, 2025, of its fiscal year, ending March 31, 2026:Consolidated revenue totaled 1,754.1 billion yen (US$11.7 billion), remaining consistent with the previous year.Consolidated operating profit totaled 107.2 billion yen (US$0.7 billion), an 11.1 percent decrease from the previous year.Consolidated profit attributable to owners of the parent company totaled 79.3 billion yen(US$0.5 billion), a 16.1 percent decrease from the previous year.“Revenue in the first quarter remained consistent with the previous year, driven by a strong increase in vehicle sales in Japan, despite a decline in revenue due to the impact of the strong yen.” said Yasushi Matsui, CFO, Executive Vice President and member of the Board of Directors of DENSO CORPORATION.“In this fiscal year, we forecast 7,200.0 billion yen (US$48.2 billion) in revenue and 675.0 billion yen (US$4.5 billion) in operating profit. Forecast of revenue will be based on reflecting the results of the first quarter, and the expected increase in revenue due to the reflection of tariff costs from the second quarter onwards. Operating profit forecast remains unchanged supported by efforts to minimize the impact of tariff costs and to steadily reflect incurred costs in pricing. Furthermore, as part of measures to enhance corporate value, it was resolved to sell DENSO’s own shares in Toyota Industries Corporation (“Toyota Industries”) and to provide advance notice of a tender offer for its own shares held by Toyota Industries.”In Japan, revenue increased to 1,013.3 billion yen (US$6.8 billion), up 2.9% from the previous year, and operating profit decreased to 13.3 billion yen (US$89.3 million), down 70.4％ from the previous year.In North America, revenue decreased to 473.2 billion yen (US$3.2 billion), down 5.4％ from the previous year, and operating profit decreased to 22.6 billion yen (US$151.1 million) down 3.0％ from the previous year.In Europe, revenue decreased to 186.9 billion yen (US$1.3 billion), down 6.4% from the previous year, and operating profit increased to 5.2 billion yen (US$34.9 million), up 4.4% from the previous year.In Asia, revenue decreased to 459.0 billion yen (US$3.1 billion), down 0.5％ from the previous year and operating profit increased to 47.7 billion yen (US$318.8 million), up 33.3% from the previous year.In other areas, revenue increased to 30.1 billion yen (US$0.2 billion), up 4.0％ from the previous year, and operating profit decreased to 5.5 billion yen (US$36.9 million), down 7.3％ from the previous year.For more details, please see the link below (detailed data).https://www.denso.com/global/en/news/newsroom/2025/20250731-g02/About DENSO CORPORATIONGlobally headquartered in Kariya, Japan, DENSO is a 7,161.8 billion yen leading mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in around 180 facilities worldwide to provide opportunities for rewarding careers and to produce cutting-edge electrification, powertrain, thermal and mobility electronics products, among others, that change how the world moves. In developing such solutions, the company’s 158,000 global employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. DENSO spent around 8.6 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2025. For more information about DENSO’s operations worldwide, visit https://www.denso.com/global Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Japan, July 31, 2025 - (JCN Newswire via SeaPRwire.com) –Honda Motor Co., Ltd. today launched a teaser page on its company website to share information on the all-new Prelude, which is scheduled to go on sale in September 2025.The all-new Prelude is a specialty sports model which represents the unrelenting Honda sports mindset, carrying forward the “joy of driving” into the electrified era, while also pursuing environmental performance and everyday usability.All-New Prelude Teaser Page: https://www.honda.co.jp/PRELUDE/new/All-new PreludeOverview of all-new PreludeGrand Concept: “Unlimited Glide” — Endless driving pleasure & Extraordinary experience —Inspired by the image of gliders soaring freely and boundlessly through the open sky, Honda developed the all-new Prelude under the grand concept of “Unlimited Glide,” striving for a vehicle that evokes the uplifting sensation of gliding gracefully through the air and extraordinary experience that people do not have in their everyday lives.Like a glider, with proportions that epitomize a universally recognized functional beauty with widespread wings and which glides through the air while making dynamic yet smooth turns, the all-new Prelude was designed to offer a special driving experience that arouses the desire to keep on driving. Equipped with a further advanced e:HEV, original Honda hybrid system, this model will become the “prelude” for future Honda specialty sports models in the electrified era. Exterior designThe all-new Prelude features a low, sharp front nose and smooth, yet expressive body lines, which contribute to the uplifting sensation of gliding through the air, as well as a low and wide stance that evokes a sense of dynamic driving. Moreover, this model is characterized by a number of unique design features such as the headlight design inspired by gliders, smooth and clean door panels with flush outer door handles, and the black chrome-plated front grille that express the sense of premium quality and sophistication, embodying what Honda pursues in its specialty cars.Interior designDesign evoking the uplifting sensation of gliding through the air was also applied to the interior of the all-new Prelude, ensuring a comfortable space not only for the driver but the front passenger as well. The grand concept of the all-new Prelude was expressed with the main interior color combination of fresh white and deep blue. The instrument panel design evokes a sense of exclusivity through its fine detailing such as the softly shaded white surface material that makes it irresistible to touch and the embroidered Prelude logo in front of the passenger seat.The front seats were designed differently to suit separate needs: the driver’s seat holds the driver in place even during sporty driving, while the passenger seat offers comfort together with just the right amount of feeling of being enveloped. Other unique interior design features, such as a low and horizontally expansive line of sight, a D-shaped steering wheel and full-graphic meters designed exclusively for Prelude, are enhancing a sense of anticipation for an exceptional driving experience this vehicle can offer.Package designAs a new-generation specialty car that offers new value to the customer, the all-new Prelude features a package design that achieves seemingly conflicting qualities—specialty and versatility.While a wide, low and smoothly sculpted body realizes the proportions worthy of a specialty sports model, the large-diameter tires and an optimized wheelbase enable the all-new Prelude to demonstrate its outstanding dynamic performance.In addition, a cargo space features a large-opening liftback that makes loading and unloading easy, split-folding rear seats that enable versatile cargo loading, as well as an underfloor storage compartment and convenient hooks, to realize a user-friendly cargo space. History of Honda PreludeEver since the launch of the first-generation model in 1978, spanning five generations, Honda Prelude has always been at the forefront of the times as an advanced FF (front-engine, front-wheel-drive) specialty model featuring cutting-edge technologies of the times, including: the first Japanese model to feature an electric sunroof, anti-lock brake system (ABS), and the world’s first four-wheel steering (4WS) system. After a 24-year hiatus, with this 6th-generation model, the Prelude will return to the market as a hybrid specialty car suitable for the electrified era. Copyright 2025 JCN Newswire via SeaPRwire.com.

Developing dual-use UAVs for civil and defense applicationsAutomating the transport of heavy cargo with MHI's multi-purpose medium-sized UAVAccelerating the transport of medications using a VTOL (vertical take-off and landing) UAV capable of flying long distances at high speedTOKYO, July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) participated in a practical training exercise held on July 17 at the Japan Ground Self-Defense Force (JGSDF) Asaka Garrison (Nerima-ku, Tokyo), aimed at improving response capabilities in the event of an earthquake centered on the Tokyo metropolitan area. The training was conducted by the JGSDF Eastern Army in cooperation with local governments, with MHI joining at the request of the Japan UAS Industrial Development Association (JUIDA). MHI conducted training to transport relief supplies to isolated disaster victims using its medium-sized multirotor uncrewed aerial vehicle (hereinafter "medium-sized UAV") currently being developed by its Commercial Aviation Systems division, and the VTOL (vertical take-off and landing) UAV being developed by the Integrated Defense & Space Systems division.The medium-sized UAV is being developed for a variety of purposes, such as transporting relief supplies in the event of a disaster, providing logistics support to remote islands and mountainous areas, and conveying materials for construction work on power transmission towers. It has conveyance functionality with enhanced wind resistance during takeoff and cruising, and an automatic unloading function that allows the cargo to be lowered at the destination with a winch from a hovering state without having to land. For this exercise, MHI conducted a loading demonstration of relief supplies, and a flight demonstration. Going forward, MHI will pursue further functional improvements such as incorporation of satellite communication capabilities, and extension of the cruising range with a hybrid power system.(Note)The VTOL UAV is being developed for the purpose of quickly delivering relief supplies to remote islands and ships in transit. It is capable of high speed flight over long distances of up to 1,000 kilometers, and can take off and land even in places without runways. For this exercise, MHI took advantage of the maneuverability and vertical take-off and landing capabilities of the VTOL UAV to demonstrate quick delivery of medicines to disaster areas.MHI will continue to pursue the development of dual-use UAVs with consideration for both civil and defense applications, and through their use, work to provide solutions for various societal challenges.Medium-sized UAV used during training for the transport of relief suppliesVTOL UAV used during training for the transport of relief suppliesNote: Using an engine to generate electricity.Specifications of the Medium-Sized UAVPayload (maximum): 200kgCruising range: 15km (battery type), 200km (hybrid type under development)Dimensions: Overall length approx. 6mMotive power: Battery type, Hybrid type (under development)Ease of transport: Can be transported by truck to takeoff/landing pointsAdditional equipment for demonstration testing: Automatic unloading system using a winch, relief supplies transport containerSpecifications of the VTOL UAVPayload (maximum): 5kgCruising range: 1,000kmDimensions: Overall length approx. 2.4m, main wingspan 3.4mMotive power: For fixed-wing propulsion: EngineFor multicopter: Electric motorsAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2025 JCN Newswire via SeaPRwire.com.

- Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease- 56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four YearsTOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, Canada, and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Four Years of Lecanemab Therapy Helped Patients Slow the Progression of AD and Remain in the Early Stages of AD Longer Compared to AD’s Natural Course Clarity AD is a global Phase 3 placebo-controlled, double-blind, parallel-group, randomized study to evaluate lecanemab 10 mg/kg bi-weekly IV treatment of early Alzheimer's disease, which involved 1,795 patients(treatment group: 898, placebo group: 897). 95% of patients who completed the core study (18 months) chose to continue in the open-label extension study (OLE), with 478 patients still receiving treatment for four years. In the Clarity AD core study, the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale.To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person’s ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.1,2Over three years of treatment, including both the core study and the OLE, data showed lecanemab demonstrate da reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)** cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when bench marked against the expected decline in the BioFINDER*** cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four years mark. For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202554pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. Only lecanemab fights AD in two ways—targeting both protofibrils and plaque, which can impact tau accumulation downstream.Importance of Ongoing Treatment and SC Development ProgramDue to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped1, Eisai is investigating a new lecanemab SC maintenance treatment option following 18 months of IV therapy so patients can continue to fight this progressive, relentless disease.Clinical trials of lecanemab SC were conducted as a sub-study of the open-label extension (OLE) following the core Phase 3 Clarity AD study in individuals with early AD, to evaluate a range of doses administered by SC vial or autoinjector. Eisai has developed a SC-AI for maintenance therapy at a dose of 360 mg weekly and a500 mg SC-AI is being developed for initiation dosing. Similar Impact on Clinical Outcomes and Biomarkers with IV and SC DosingThe pharmacology (PK/PD), clinical (efficacy endpoints such as CDR-SB) and biomarker (amyloid PET and blood biomarkers) relationships established with extensive clinical data supported the FDA approval of IV maintenance therapy after the initial 18 months of treatment and support the investigational SC maintenance dose option.- Data supports that transitioning to a weekly 360 mg SC AI dose of lecanemab after 18 months of initiation dose (10 mg/kg IV biweekly) maintains clinical and biomarker benefits comparable to continued biweekly IV dosing.- Clinical and biomarker responses at 48 months with monthly IV maintenance dosing are similar to the responses with ongoing biweekly dosing whether patients are amyloid positive (>30 CL) or negative (

TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways– targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of real-world clinical treatment with lecanemabat 15 medical centers in the U.S., with a final report scheduled for late in the third quarter of Eisai’s fiscal year ending March 31, 2026. This presentation serves as an interim report as of July 1, 2025.Patient Baseline and Actual Treatment Situation The interim study collected information on 178 people living with early AD from nine US medical centers using a standardized case report format. The disease stage of the patients at baseline was mild cognitive impairment (MCI) due to AD in 57.6% and mild AD in 42.4%. The average age of the patients was 74.2 (±6.6) years, and the ratio of men to women was 44.6 to 55.4.The mean duration of lecanemab treatment was 375.4 days (± 182.8 days). The mean time from diagnosis to first treatment was 224.2 days (± 295.4 days) and the mean number of lecanemab treatments was 24.8 (± 11.5). At the time of case reporting, 87.4% of patients (152 patients) were continuing treatment with lecanemab. Adverse events leading to discontinuation of treatment included ARIA-E (ARIA-edema/exudation) in two patients (1.1%), ARIA-H(ARIA-cerebral microbleeds, cerebral hemorrhage and superficial hemosiderin deposition) in two patients (1.1%),and concomitant ARIA-E and ARIA-H in one patient (0.6%). Three patients (1.7%) discontinued due to adverse events other than ARIA. In addition, 11 patients (6.3%) reported discontinuing the treatment for personal reasons or at the discretion of their doctor or the individual.In this study, 83.6% of patients either remained at the same clinical stage or improved from mild dementia to MCI (stable: 76.9%, improvement: 6.7%). Additionally, at time of interim data cut, 86.7% of patients who had received 40 or more doses over 18 months remained stable or showed clinical improvement (stable: 66.7%,improvement: 20.0%:).Of the 178 patients, ARIA was observed in 23 (12.9%). 14 (7.9%) were observed to have ARIA-E, of which 12(6.7%) were asymptomatic. ARIA-H was present in 11 patients (6.2%), all of whom were asymptomatic. Infusion reactions were observed in four patients (2.2%). Additionally, no serious bleeding events or deaths were reported. Impact of APOE4 Status Of the 178 patients in this study, 12 were excluded with unknown status. Among the remaining 166 patients,30 (18.1%) were APOE 4 homozygotes, 84 (49.4%) were heterozygotes, 54 (32.5%) were non-carriers. Generally, the proportion of homozygotes among people with AD is thought to be 15% or more.The incidence of ARIA was 20.0%, 9.8% and 14.8% in homozygous carriers, heterozygous carriers and noncarriers, respectively (45.0%, 19.0% and 13.0% respectively in the Phase 3 Clarity AD 18-month core study). The incidence rate of ARIA-E and ARIA-H were 13.3% and 10.0%, respectively (32.6% and 39.0% in the Clarity AD core study), which is within the FDA-approved label range. The majority of ARIA cases (0.13%) were asymptomatic. The incidence of adverse events leading to discontinuation was 16.7% in homozygous carriers,2.4% in heterozygous carriers and 5.6% in non-carriers.73.3% of homozygote patients’ clinical stage remained stable or improved (stable: 66.6%, improved: 6.7%),88.0% of heterozygotes patients’ clinical stage remained stable or improved (stable: 83.0%, improved: 4.9%)and 85.2% of non-carrier patients’ clinical stage remained stable or improved (stable: 75.9%, improved: 9.3%).Utilization of Blood-Based Biomarkers (BBMs)BBMs are being developed in AD to identify brain AB pathology and are intended for use in prescreening (triage)and confirmatory diagnosis. Of the 178 patients in this study, 49 patients (27.5%) were diagnosed using BBMs. In some of these cases (11 patients, 6.1%), it was also used for confirmatory diagnosis. Data collected from clinical practices showed the volume of tests doubling every 4 to 8 months, with BBMs using p-tau217 growing most rapidly.Satisfaction with Lecanemab Treatment The results of a physician, patient and care partner lecanemab satisfaction survey was presented. The survey was based on questionnaires and interviews with nine U.S. physicians and evaluated treatment from multiple perspectives, including efficacy, safety and quality of life (QOL).In the physicians’ evaluation, the average satisfaction level for the treatment efficacy and safety (out of 10) was8.7. The scoring criteria included: cognition 8.1, daily function 8.1, behavioral/neuropsychiatric symptoms 7.9and QOL 8.0. The satisfaction level of the patients as assessed by physicians was 8.8, and that of the care partners was 8.2. These results highlight the favorable evaluation of lecanemab’s efficacy and safety in real world clinical practice and reinforce its therapeutic value.Note: Retrospective real-world studies can be very valuable in providing additional information to complement clinical trial data. However, there may have several limitations to keep in mind:Potential for BiasesData Completeness and ConsistencyData may be collected inconsistently since data collection is completed by different people at independent3 sites.* Mitigation: Data inconsistency is pursued by providing site access to standardized electronic case-report forms.Lack of Control GroupInterpretation of data may be limited since real-world studies do not utilize placebo-controlled armsConfounding VariablesConfounding variables are not controllable, which may impact the relationship between the exposure and outcome.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are thought to be the most toxic AB species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble AB plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202552pdf.pdfMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOYOTA CITY, July 30, 2025 - (JCN Newswire via SeaPRwire.com) - Toyota Motor Corporation announces its sales, production, and export results for June 2025 as well as the cumulative total from January to June 2025, including those for subsidiaries Daihatsu Motor Co., Ltd. and Hino Motors, Ltd.For more details, please see the link below (detailed data).Click here for detailed sales, production, and export results ("Detailed data (Excel)")URL https://global.toyota/en/company/profile/production-sales-figures/202506.html Copyright 2025 JCN Newswire via SeaPRwire.com.

Santa Clara, CA, July 29, 2025, (ACN Newswire via SeaPRwire.com) - Meshy.ai, the world’s leading AI-powered 3D content generation platform, has launched the Meshy 5 Preview, offering early access to the next generation of AI 3D model generator. Built on the strong foundation of Meshy 4, this preview version introduces smarter generation tools, enhanced image alignment, sharper geometry, and over 500 new animations—empowering creators to build faster, cleaner, and more creatively than ever before.Trusted by 3 Million Creators – The Platform of Choice for Game DevelopersWith over 30 million 3D assets generated and a community of more than 3 million creators, Meshy has become the go-to AI platform for game developers, VFX artists, and 3D content professionals worldwide. Recognized by Andreessen Horowitz (a16z) as the only 3D tool featured in its list of “Most Popular AI Tools Among Game Developers,” Meshy is redefining how digital worlds are built—with speed, accuracy, and creative control.What’s New in Meshy 5 PreviewStronger Image Alignment: Mesh structures now more precisely match the shape and proportions of input images — with support for multi-view input to generate more complete 3D models.Razor-sharp Geometry: From hard-surface mechs to organic characters, edges are sharper and forms more defined.Advanced AI Tools: Now supports Kontext for multi-view generation and a smart AI Prompt Helper to make prompting faster and easier.500+ New Animations: A dramatically expanded animation library for rigged characters, empowering developers and artists with more expressive motion capabilities.“The multi-view support and sharper geometry have made our modelling workflow twice as fast with much less cleanup,” said Victoria C., a senior 3D environment artist at an indie game studio and early Meshy 5 Preview tester. “This version brings us much closer to using AI directly in our production pipeline.”From Meshy 4 to Meshy 5 Preview: A Foundation ReinforcedAbout one year ago, Meshy introduced Meshy 4, which brought improvements in geometry quality, Text to 3D workflow, and retry functionality. Meshy 5 Preview builds on that foundation, offering enhanced mesh coherence, fewer visual defects, and a more structured modelling-to-texturing pipeline—allowing creators to move from concept to completion with unprecedented speed and clarity.Whether generating stylized concepts or rigged production assets, Meshy empowers studios to accelerate creative pipelines, reduce manual workloads, and retain full artistic control. The platform integrates seamlessly with tools like Unity, Unreal Engine, Blender, and ZBrush, and supports advanced rigging and animation workflows out-of-the-box.What Sets Meshy ApartPowered by cutting-edge foundation models, Meshy combines advanced AI technology with industry-leading product capabilities to deliver unparalleled value. Its unique features and user-centric design have established Meshy as the world’s leading AI 3D model generator. Key differentiators include:Hyper-Realistic Texture Generation – Capable of producing highly detailed, natural-looking textures that align with industry standards.Advanced Rigging and Animation Support – Offers ready-to-use rigged models alongside an expanding motion library, significantly streamlining animation workflows.A Thriving Community for Remix & Creative Collaboration – Hosts a vast repository of high-quality, customizable assets, enabling creators to easily remix and build upon existing work.Unmatched Workflow Flexibility – Supports both white and textured model outputs, along with texture swapping via text or images. Artists can effortlessly re-style assets — for example, transforming a realistic model into an ink-wash aesthetic — without starting from scratch.Real Creators. Real Workflows. Real Impact.From indie game developers and VFX artists to educators and avatar designers, creators around the world are embracing Meshy 5 Preview to reimagine the way they build, teach, and tell stories in 3D. Whether it’s speeding up asset production, unlocking new creative directions, or making 3D design accessible to more people—Meshy is becoming a core part of real-world workflows.Explore how Meshy is powering next-gen creativity—one creator at a time.Sivan Okcu – Avatar Creator for Second LifeUses Meshy’s Text to 3D and Image to 3D features to produce stylized avatars faster, reduce costs, and grow his virtual business.“I can explore more styles, lower prices, and sell more—all without sacrificing quality.” Read Sivan’s story → Skylyfe Inc. – Tech Education for Underserved YouthEmpowers students aged 10–30 with hands-on 3D design using Meshy in an 8-week program focused on 3D printing, AR, and VR.“Students said it felt like printing things from your mind into real life.”Read the Skylyfe story → Marcos Medel – VFX Artist & AnimatorTransforms classical paintings into surreal 3D cinematic loops using Meshy to create custom models with AI-enhanced workflows.“Something that could take days or weeks — Meshy can do in just a few clicks.” Read Marcos’s story → David Zhang – Indie Game Developer (Remnants of R’lyeh) Builds weapons, creatures, and deep-sea props using Meshy’s Text-to-3D, accelerating production and enriching a Lovecraft-inspired horror world.“Meshy helped bring my game’s vision to life—faster, cheaper, and more creatively.” Read David’s story → Read More User Stories in the Meshy BlogWhether you’re a creator with a cool workflow or an influencer interested in collaborating, share your project with us at marketing@meshy.ai.Media Contact: Conan Zhang, Meshy.ai, marketing@meshy.ai, www.meshy.ai Distributed by Pinion Newswire. All rights reserved. Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 30, 2025 - (JCN Newswire via SeaPRwire.com) - Sharp Corporation has reached an agreement with Mitsubishi Chemical Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Manabu Tsukimoto), the National Institute of Information and Communications Technology (NICT) (Headquarters: Koganei City, Tokyo; President: Hideyuki Tokuda), and TECHLAB Co., Ltd. (Headquarters: Tama City, Tokyo; President: Hiroshi Hatakeyama) to collaboratively develop ultra-compact and lightweight LEO (Low Earth Orbit) satellite communication user terminals for mobility applications.Left: Ultra-Compact and Lightweight LEO Satellite Communication User Terminal;Right: An Image of the Terminal Installed in a VehicleLEO satellite communication enables high-quality, high-speed connectivity even in challenging environments such as mountainous regions, at sea, and on remote islands. Sharp began developing LEO satellite communication user terminals in 2023 (*2), applying design and communication technologies honed through smartphone development to create a compact model (approximately 446 x 446 x 66mm) weighing around 7kg. The goal of this agreement is to accelerate efforts towards practical implementation by fiscal 2025, targeting deployment on vessels and other platforms.With this new agreement, the development of even smaller and lighter LEO satellite communication user terminals will commence in collaboration with Mitsubishi Chemical, NICT, and TECHLAB. A form factor about one-tenth the size (approximately 200 x 200 x 30mm and 1kg) of the currently developed terminal will be aimed through the development of lightweight, high thermal conductivity composite materials and superior heat dissipation designs. By enabling deployment on mobility platforms such as drones and vehicles, applications of LEO satellite communication will be significantly expanded, ensuring communication lines in mountainous areas and disaster zones, enabling real-time location data transmission, and facilitating usage in autonomous vehicles.This initiative will be showcased at the Sharp booth (*2) (South Exhibition Hall, Satellite Data and Space Utilization Area S6-34) and at the Mitsubishi Chemical booth (S7-11) during the "SPEXA - [International] Space Business Exhibition 2025," held at Tokyo Big Sight (Koto-ku, Tokyo) from July 30 (Wednesday) to August 1 (Friday).Roles of Parties Involved- Sharp: Development of LEO satellite communication user terminals utilizing miniaturization and communication technologies cultivated in smartphone design.- Mitsubishi Chemical: Development of new lightweight, high thermal conductivity composite materials for heat dissipation plates.- NICT: Overall design and simulation of antennas for ultra-miniaturization and lightweight structures, including heat dissipation designs.- TECHLAB: Material molding and processing of new materials.Contacts:NTN_B5G@sharp.co.jp*1 This terminal integrates LEO satellite communication antennas and modem functions. LEO stands for Low Earth Orbit.*2 The development of LEO satellite communication user terminals and participation in SPEXA is supported by a grant from the National Institute of Information and Communications Technology (NICT). (JPJ012368G50501) Copyright 2025 JCN Newswire via SeaPRwire.com.

Mitsubishi Heavy Industries aims to integrate DCIM (Data Center Infrastructure Management) into its One-stop solutions portfolio to offer digital services to data centersThe combination delivers a comprehensive view of data center infrastructure, enabling enhanced visibility, elevated operational efficiency and optimized energy consumptionTOKYO, July 29, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has concluded an agreement with Modius® Inc., a US based provider of innovative software solutions for managing critical facilities for the data center and telecommunications markets. Under this agreement, MHI will integrate Modius's OpenData® DCIM technology with MHI's power, cooling, and control technologies to deliver a unique, market leading solution for Data Center Energy Management (DCEM). This collaboration is an example of MHI Group's partnering efforts, and MHI Group will continue to build strategic partnerships globally.Modius's OpenData DCIM platform provides real-time insights into data center infrastructure, enabling capacity management, improved uptime and enhanced energy efficiency. With over 250 deployments worldwide, Modius has gained customer trust for delivering reliable and sustainable solutions that optimize operations and reduce environmental impact.With rapid scaling of digital infrastructure globally and frequent upgrades to IT systems, it is becoming an overwhelming challenge to manage the reliable operation of data centers while also being energy efficient. The OpenData® AI/ML module strengthens MHI's One-stop Solutions Portfolio by enabling real-time anomaly detection and proactive diagnostics. By self-learning the "normal" behavior of data centers, the AI system empowers operators to address issues before they escalate. By combining Modius's real time monitoring and AI/ML driven analytics with MHI's cutting-edge engineering solutions, the joint offering will empower customers to proactively manage capacity, minimize downtime, and improve sustainability."MHI is committed to delivering sustainable and energy efficient data center solutions," said Shin Gomi, Senior General Manager, DCEM at MHI. "With the addition of the Modius DCIM platform to our digital solution portfolio, we can offer digital services to both existing and new customers seeking enhanced visibility and optimization for building next-generation data centers.""MHI's global presence and its alignment with our mission to drive efficiency, improve sustainability, and optimize performance in data centers make this collaboration a perfect fit," said Craig Compiano, President at Modius. "We are excited to work with MHI to deliver our DCIM solutions alongside their advanced technologies to customers worldwide.Mitsubishi Heavy Industries Group is delivering more sustainable and reliable solutions to data centers by combining decarbonized power generation, reliable power distribution, high efficiency cooling systems and Integrated Digital Solutions. We support our customers through the complete lifecycle from design phase to post deployment with actionable insights, solutions and services.About ModiusModius Inc. is a leading innovator in Data Center Infrastructure Management (DCIM) solutions, providing real-time visibility and decision support for managing distributed equipment across data centers, telecommunications networks, and other critical facilities. The company's flagship product, OpenData, is an edge-ready asset performance management platform designed to optimize the availability, capacity, and efficiency of critical infrastructure. For more information about Modius Inc. and the OpenData platform, please visit Modius.comAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2025 JCN Newswire via SeaPRwire.com.

Osaka, Japan, July 29, 2025 - (JCN Newswire via SeaPRwire.com) - Osaka Prefecture has finalized the detailed program for the OSAKA JAPAN SDGs Forum to be held on Friday, September 5, 2025.Under the Osaka SDGs Vision (formulated in 2020), Osaka Prefecture has set the goal of becoming a leading “SDGs advanced city” that contributes to achieving the SDGs on a global scale as the host city of the Osaka-Kansai Expo. To achieve this, Osaka is working collectively to create new SDGs initiatives. As part of these efforts, the OSAKA JAPAN SDGs Forum will be held at the Expo Hall “Shine Hat” located within the Osaka-Kansai Expo venue. This forum, traditionally organized as the National SDGs Forum by various local governments, will now take place at the Expo venue under the theme “EXPO for SDGs.” Its aim is to share pioneering actions with domestic and international audiences and to encourage all participants to think together about the future beyond 2030, “SDGs + beyond.” The forum’s concept, “Connecting Everyone’s Wisdom to Change the World,” will bring together diverse stakeholders, including SDGs experts from the United Nations, private companies and local governments committed to SDGs, as well as members of the youth generation, breaking down barriers to collaborate toward a sustainable future.The opening address will be delivered by Osaka Governor Hirofumi Yoshimura, and the keynote speech will be given by Professor Norichika Kanie, a leading authority on SDGs and one of 15 independent scientists appointed by the UN Secretary-General to contribute to the Global Sustainable Development Report (GSDR 2023). In addition, Ryoko Aoyagi, Country President of Schneider Electric Japan, will deliver a special lecture. Schneider Electric has been recognized as the world’s most sustainable company for two consecutive years by TIME Magazine and Statista, and is renowned for its pioneering initiatives in advancing the SDGs.The panel discussion will feature Toshihiro Michioka, Representative Director and Deputy President of Sumitomo Mitsui Banking Corporation, Ryuichi Kouno, Managing Director of Mandai Co., Ltd., and Yasumi Takahashi, Executive Officer and Head of SCM at Ezaki Glico Co., Ltd. The session will be moderated by Tsutomu Sasaki, Chief Specialist at the Japan Research Institute, Ltd. The discussion will focus on the “Genkotsu Project,” a collaborative initiative by Osaka Prefecture and private companies aimed at promoting consumer behavior change toward decarbonization, along with the specific actions that government, industry, and the public can take. In addition, the program will feature a performance by Mitsuko Nakamura, an enka singer who has long supported assistance dogs-related initiatives.The forum will conclude with a panel discussion featuring Toshihiko Ota, Mayor of Toyota City, the next host city of this forum, Yumi Otsuka, Chief Sustainability Officer for Toyota Motor Corporation, and Professor Norichika Kanie.We invite companies, local governments, NGOs, and students who are interested in the SDGs to join us.Please see this link for details: OSAKA JAPAN SDGs ForumOverview1. Date and Time: 13:00 to 17:30, Friday, September 5, 2025 (venue opens at 12:00)2. Venue: Expo Hall “Shine Hat” (inside the Osaka-Kansai Expo site)3. Eligible Participants: Students, academics, and groups such as corporations, local authorities, or NPOs interested in the SDGs4. Capacity and Participation Fee: 1,300 personsParticipation Fee: Free (*please note that a separate ticket is required for entry to the Expo site)5. Program (Tentative): *This is the current plan, but please note that the program is subject to change.PROGRAMSpeakers/OverviewPart 1: 13:00 to 15:15Opening Ceremony- DAZZLE Dance Company- BOTAN Dance Unit- Approx. 70 people, including disabled persons, selected through open recruitmentThey will put on a dance performance entitled “Hikari Musubi”Greetings from HostOsaka Governor Hirofumi YoshimuraGreetings from GuestsUnited Nations agencies and othersKeynote SpeechDr. Norichika Kanie, Deputy Director Keio STAR, Head of the SFC Laboratory xSDG Laboratory, Professor at the Graduate School of Media and Governance of Keio UniversityWe will welcome Professor Norichika Kanie of Keio University, a leading researcher in SDGs in Japan, and one of the 15 independent scholars appointed by the Secretary-General of the United NationsSpeechRyoko Aoyagi, Country President of Schneider Electric JapanRyoko Aoyagi, Country President of Schneider Electric Japan, a company ranked No.1 for two consecutive years in TIME Magazine’s "World’s Most Sustainable Companies 2025," is confirmed to speak at the eventPanel Discussion- Toshihiro Michioka, Representative Director and Deputy President of Sumitomo Mitsui Banking Corporation- Ryuichi Kouno, Managing Director of Mandai Co., Ltd.- Yasumi Takahashi, Executive Officer and Head of SCM at Ezaki Glico Co., Ltd.- Koji Harada, Manager, Department of Environment, Agriculture, Forestry and Fisheries, Osaka Prefecture- Moderator: Tsutomu Sasaki, Chief Specialist, The Japan Research Institute, Ltd.Osaka Prefecture and private companies participating in the “Genkotsu” CO2 Reduction Project, which aims to promote consumer behavioral changes for decarbonization, will share insights on what industry, government, and citizens, can doBreakPart 2: 15:25 to 17:30 (target)Resumed ContentEnka singer Mitsuko NakamuraPerformance by Mitsuko Nakamura, and awareness-raising about assistance dogsSpeechDr. Shun Kawakubo, Associate Professor, Faculty of Science and Technology, Keio University, and Member of the Osaka Prefecture SDGs Experts CommitteeFollowing an introduction of the results of a data analysis of Osaka Prefecture's "My SDGs Declaration Project," Dr. Kawakubo will present hints for further accelerating future actions towards achieving the SDGsPresentationStudents from Kansai University Hokuyo Senior High School, Yamawaki Gakuen Senior High School, and othersMessage from the youth generationPresentations from the winning teams from the "6th Kansai SDGs Youth Action 2024," a program recognizing students' ideas and actions toward achieving the SDGsPanel Discussion- Toshihiko Ota, Toyota City Mayor- Yumi Otsuka, Chief Sustainability Officer for Toyota Motor Corporation- Professor Norichika KanieSpecial content about the city of Toyota, which will be the next host city for the SDGs National Forum. A panel discussion will be held on the theme of SDGs and partnerships.Closing Ceremony Profiles of SpeakersKeynote SpeechNorichika KanieProfessor at the Graduate School of Media and Governance, Keio University Director, xSDG Laboratory, Keio Research Institute at SFC Deputy Director, Keio STARSpecializing in international relations, sustainability studies, and earth system governance, Professor Kanie is one of 15 independent scientists appointed by the UN Secretary-General to contribute to the Global Sustainable Development Report (GSDR 2023). He also serves as a member of the Japanese Government’s SDGs Promotion Headquarters Roundtable, an Earth Commission Ambassador, and actively engages in international and domestic research and policy initiatives related to SDGs and global environmental issues. Holds a Ph.D. in Policy and Media.SpeechRyoko AoyagiCountry President, Schneider Electric JapanProfileJoined Schneider Electric in August 2018 as Vice President of the Power Systems Division. In May 2021, she was appointed Vice President of the Services Division. Expanding her responsibilities further, in April 2024, she also took on the role of Vice President for the Energy Management Segment Division, overseeing energy management business strategies for key focus industries. On October 1, 2024, she assumed the position of Country President of Schneider Electric Japan, where she is responsible for all of Schneider Electric’s operations in the Japanese market, including affiliated companies and joint ventures. Concurrently, she was appointed Representative Director of Schneider Electric Japan, Inc. and Schneider Electric Holdings K.K.6. How to ApplyRegistration for the forum is now open. For details, please refer to this link: OSAKA JAPAN SDGs ForumPlease note that, in addition to registering for the forum, visitors who already have an Osaka-Kansai Expo admission ticket must reserve their entry date and time for Friday, September 5, 2025, via the EXPO 2025 Digital Ticket website. Those who do not have a ticket will need to purchase one.REFERENCE: About the SDGsThe Sustainable Development Goals (SDGs) are an international agenda unanimously adopted at the United Nations Summit in September 2015.They consist of 17 global goals and 169 associated targets to be achieved by 2030, aimed at realizing a sustainable society that is inclusive and leaves no one behind.The SDGs are universal goals that not only developing countries but also developed nations must work toward, requiring the involvement of various stakeholders, including local governments.In Osaka Prefecture, initiatives are being promoted to become a leading city for SDGs based on the “Osaka SDGs Vision” formulated in March 2020.Reference: Osaka SDGs Vision: The image of an “SDGs advanced city” that Osaka strives to achieve https://www.pref.osaka.lg.jp/documents/12984/osaka20sdgs20vision~20230409.pdf Reference link: OSAKA JAPAN SDGs ForumInquiries about this matterOSAKA JAPAN SDGs Forum PR OfficeKyodo PR Co., Ltd. E-mail: sdgs-forum-pr@kyodo-pr.co.jp*Information about entering the event or reporting will be provided to members of the press separately.AD certificates will not be issued by the hosts. Please contact the 2025 Japan Expo Public Relations Office for AD certificate issue.Press release: https://www.acnnewswire.com/docs/files/2025729.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 29, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its in-house discovered tyrosine kinase inhibitor, “LENVIMA®” (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma.This approval is based on interim analysis results from the pivotal Phase III LEAP-012 trial. The results of this trial were presented at the European Society for Medical Oncology (ESMO) Annual Congress 2024 held in September 20241 and published in The Lancet in January 2025.2 In this trial, LENVIMA in combination with pembrolizumab and TACE (the "combination therapy") demonstrated a statistically significant and clinically meaningful improvement in one of the trial’s primary endpoints, progression-free survival (PFS), reducing the risk of disease progression or death by 34% (Hazard Ratio [HR]=0.66 [95% Confidence Interval (CI), 0.51-0.84]; p=0.0002) compared to TACE alone*.2 Median PFS was 14.6 months(95% CI, 12.6-16.7) in the combination therapy and 10.0 months (95% CI, 8.1-12.2) in TACE alone. 2 At this analysis, a trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was observed for the combination therapy versus TACE alone (HR=0.80 [95% CI, 0.57-1.11]; p=0.087). 2237 patients received the combination therapy and 241 patients received TACE alone.2 Treatment Emergent Adverse Events (TEAEs) occurred in 99.6% (n=236) of patients receiving the combination therapy versus 96.7% (n=233) of patients receiving TACE alone and led to the discontinuation of both study drugs in 13.1% (n=31) versus 4.1% (n=10) of patients, respectively.2 Grade 3, 4, or 5 TEAEs occurred in 82.3% (n=195) of patients receiving the combination therapy versus 47.7% (n=115) for TACE alone and TEAEs led to death in 4.2% (n=10) versus 2.5% (n=6) of patients, respectively.2Liver cancer is one of the leading causes of cancer-related deaths worldwide.3 In 2022, it was estimated there were more than 865,000 new cases globally and 367,000 in China, with more than 757,000 deaths worldwide, including 316,000 in China.3,4 China is estimated to account for more than 40% of global new cases and deaths.3,4 Hepatocellular carcinoma (HCC) is the most common type of liver cancer, representing approximately 90% of primary liver cancer cases.5 TACE has been a standard of care for patients with unresectable, non-metastatic HCC for many years. However, since many patients experience disease progression within one year6,7,8,9, new treatment options have been sought.LENVIMA monotherapy has been approved for the treatment of patients with unresectable HCC in more than 80 countries, including in Japan, the U.S., Europe and China and has made contributions to many patients to date. With this approval, it is expected that LENVIMA will further expand its contribution to patients with hepatocellular carcinoma in China.Eisai positions oncology as a key therapeutic area and is aiming to discover innovative new medicines with the potential to cure cancer. Eisai is committed to expanding the potential clinical benefits of lenvatinib for cancer treatment, as it seeks to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families and healthcare professionals.In March 2018, Eisai and Merck & Co., Inc., Rahway, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.*TACE alone: In addition to TACE, oral placebo and intravenous placebo corresponding to LENVIMA and pembrolizumab were administered.For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202551pdf.pdfMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com.

Olympus to take a significant equity stake in Swan EndoSurgical with a combined initial investment of at least $65 million.Swan EndoSurgical to develop an innovative endoluminal robotic system for less invasive therapeutic treatments.The total combined funding could reach up to $458 million if pre-agreed milestones are met and the program reaches term.TOKYO, July 25, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, today announced the conclusion of an agreement with Revival Healthcare Capital (Revival) to drive advancements in endoluminal robotics. Olympus and Revival will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed to revolutionize gastrointestinal (GI) patient care in the future.Logo of Swan EndoSurgicalEndoluminal robotics aims to empower more physicians to safely perform innovative techniques, enhancing patient access to treatment options that support safety and improved recovery times. This groundbreaking advancement has the potential to create new and significantly enhanced minimally invasive treatment options for major unmet medical needs by boosting precision and efficiency in procedures addressing ergonomic strain for healthcare professionals.Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus commented, “This partnership marks a significant milestone in our strategic initiative to advance endoluminal robotics. We are excited to enter this collaboration that we expect to play a pivotal role in reshaping the GI market by expanding procedural capabilities for physicians. This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population.”For decades, endoscopy—placing a flexible camera into an existing body orifice—has yielded early and accurate diagnoses of conditions such as GI tract cancer. In recent years, specialists, primarily gastroenterologists, have begun performing endoscopic therapeutic procedures, such as cancer resection, by inserting instruments through the endoscope. However, manual endoscopes and their instruments have limitations that make many advanced procedures within the lumen of the GI tract challenging and not widely available globally. The development of an endoluminal robot, with its ability to easily maneuver within the GI tract and deploy flexible arms, provides the opportunity for more patients to benefit from safe and effective procedures, potentially avoiding invasive surgery. This innovation allows for the early, safe, and effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. Furthermore, the technology has the potential for application in numerous other disease areas.Headquartered in the United States, Swan EndoSurgical has assembled a leadership team of highly experienced industry professionals who will drive technical, clinical, and commercial development of the robotic platform. About Swan EndoSurgical Swan EndoSurgical, Inc. is an innovative start-up co-founded by Revival Healthcare Capital and Olympus that is focused on the development of endoluminal surgical robotics with the aim to create effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. For additional information, visit the Company’s website at www.swanendosurgical.com or contact info@swansurg.com.About Revival Healthcare CapitalRevival Healthcare Capital is an investment firm focused on the MedTech sector. Revival specializes in transformative external innovation partnerships and other opportunities where its team of experienced operators and investors believes it can provide leadership, resources, and deep sector insights – beyond its capital – to further support companies' growth strategies. For additional information, visit Revival’s website at www.rvlhc.com or contact info@rvlhc.com .About OlympusAt Olympus, we are committed to Our Purpose of making people’s lives healthier, safer, and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis, and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp.Media contact:Mail: Global-Public_Relations@olympus.com Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 25, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global standards for Environmental, Social and Governance (ESG). Eisai received particularly high scores in “Corporate Governance”, “Anti-Corruption”, “Tax Transparency”, “Labor Standards”, “Customer Responsibility”, and “Water Security”. As of the end of June 2025, 2,045 companies worldwide and 278 Japanese companies were included in the FTSE4Good Index Series.In addition to the MSCI Selection Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Nihonkabu ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN), the S&P/JPX Carbon Efficient Index and the Morningstar Japan ex-REIT Gender Diversity Tilt Index, which are ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).Eisai’s corporate concept is to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides to them, as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this concept.For more information on our sustainability initiatives, please visit https://www.eisai.com/sustainability/index.html.Also, we post and share related information on X, LinkedIn and Facebook.Media Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com.

Kawasaki and Nagoya, Japan, July 24, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and Nagoya University, a member of the Tokai National Higher Education and Research System (THERS), have jointly developed a technology to encourage the use of new transportation services and eliminate transportation gaps. The “social acceptance model-based simulation (SAMSIM)” simulates how psychological factors influence residents' willingness to use new transportation options and combined with AI-powered digital rehearsal technology, it allows for proactive evaluation of strategies to ensure successful service adoption.Ride-sharing and self-driving cars have emerged as ways to address transportation gaps as populations age and driver shortages persist. However, the ease with which these new services are accepted varies depending on various psychological factors such as perceived safety, trust, and usefulness. To promote usage of these services, it is necessary to accurately understand the psychological factors that impact people's willingness to try them create measures that encourage behavioral change.Simulations using this technology showed that strategically timed and targeted public awareness campaigns could increase usage intent by approximately 20%. This research is a key outcome of the Fujitsu-Nagoya University Social Digital Twin Research Division at the Fujitsu Small Research Lab [1]. A demonstration of the technology will be accessible through the Fujitsu Research Portal starting August 1, 2025.Overview and background of the technologyThe "Social Acceptance Model," developed by Nagoya University, provides a framework for understanding the psychological drivers behind transportation choices. By integrating this model with Fujitsu's agent simulation digital rehearsal technology, which accurately reproduces and predicts human behavior on digital twins, the system can assess how various interventions – such as targeted advertising or other service improvements – will affect residents' perceptions and consequently their willingness to use the service.To verify the effectiveness of this technology, Fujitsu utilized the data from a field experiment of an on-demand ride-sharing taxi service conducted by Kawanishi Town in Nara Prefecture and CHUO FUKKEN CONSULTANTS CO.,LTD. in fiscal year 2023. In addition, Nagoya University conducted a 48-point survey to clarify the psychological factors that influence the intention to use on-demand ride-sharing taxis and obtained responses from approximately 1,200 people (15% of the local population).Based on this survey data, the simulation was built to replicate residents' choices regarding the service. The model succeeded in reproducing the actual usage trends of on-demand transportation in Kawanishi Town, achieving accuracy of 90%.Using this simulation, the two parties optimized two key measures – "public awareness activities" and "service expansion by increasing the number of vehicles" – for the two psychological factors that were estimated to have a strong impact on usage intention: "awareness of the service" and " perceived usefulness." The simulation specifically revealed that strategically improving the timing and frequency of the distribution of promotional materials and the increase of the number of available taxis could significantly reduce reservation failures and boost usage intention by approximately 20%, leading to a greater service sustainability.Figure 1: Overview of social acceptance model-based simulationFigure 2: Overview and results of the initiativesIsao Kita, Director of the Comprehensive Policy Division, Kawanishi Town, Nara Prefecture, comments:“I believe that pre-emptive consideration of transportation policies based on digital rehearsal technology will make it easier for local governments to consider measures amidst increasingly complex social issues. The possibilities are fascinating.”Future plansBy fiscal 2026, Fujitsu and Nagoya University will continue to conduct demonstration experiments and aim to develop this technology into a solution that suggests measures to improve adoption of new transportation services using data gained from small-scale resident surveys. Going forward, both parties will apply this technology to the design of public services in a wide range of fields, including healthcare, medicine, urban development, and environmental measures, in addition to the mobility sector, thereby improving people's well-being through converging technologies that combine the digital realm and humanities and social sciences.[1] Fujitsu Small Research Lab:Established in 2023. Fujitsu researchers reside or stay long-term at universities to accelerate joint research, discover new themes, develop human resources, and build medium- to long-term relationships with universities.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout Tokai National Higher Education and Research System – Nagoya UniversityBoasting a free and vibrant academic culture, Nagoya University has produced prominent leaders in Japanese industry through its globally renowned research and achievements, which have led to the awarding of Nobel Prizes to six Nagoya University scientists.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesTokai National Higher Education and Research System – Nagoya UniversityPhone: 052-789-5773kouho@t.mail.nagoya-u.ac.jp Copyright 2025 JCN Newswire via SeaPRwire.com.

- Rationalization of domestic production technologies and strengthening of the system in Japan for manufacturing divertor outer vertical targets for ITER- Seeking to contribute to the ITER Project and provide components for the prototype reactor for fusion energy and startup machinesTOKYO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, "Hitachi") and the National Institutes for Quantum Science and Technology (“QST”) began developing a second prototype, a full-scale mockup of an outer vertical target*1 which is one of the most important components of a divertor in January 2022. Divertors are important pieces of components used in the ITER fusion*2 experimental reactor that is under construction in Southern France. With streamlining the production method through measures such as the introduction of an automatic welding system as detailed below, we completed the second prototype in March 2025. Furthermore, we today announce that a high-heat-load sample of an outer vertical target has passed the rigorous certification test by the ITER Organization, which constructs and operates ITER as an international organization. Hitachi's production technologies have earned significant recognition following the preceding company which completed the first prototype with QST in July 2024.*1 QST will deliver 58 outer vertical targets to the ITER Organization. The preceding company manufactured 18 of these. The company that will manufacture the remaining 40 targets will be decided later.*2 Fusion is the source of the energy that keeps the sun shining. To realize fusion energy on Earth, it is necessary to use nuclear fusion reactions where deuterium, tritium and other light atomic nuclei fuse in a plasma state and become heavier atomic nuclei such as helium. Lithium, the raw material for tritium, and Deuterium are abundantly available in seawater. Additionally, the generation of fusion energy does not result in the generation of CO₂. For this reason, fusion energy is expected to fundamentally solve energy and environmental issues. See *5 regarding plasma.Utilizing the technologies and knowledge obtained through the production of the prototype, Hitachi and QST will continue to contribute to the promotion of the ITER Project and also cooperate in the development of technologies for realizing fusion energy in the future. In addition, Hitachi seeks to provide divertors and similar in-vessel components to fusion energy-related startups and a prototype fusion reactor for which QST is investigating the design.The second prototype outer vertical targetHigh-heat-load sample of an outer vertical targetOutline of ITER and divertorsTo realize fusion energy, seven regions including Japan, Europe, the United States, Russia, South Korea, China and India are promoting the ITER Project, a large international project aimed at conducting scientific and technological demonstrations of fusion. With the goal of achieving full operation through nuclear fusion burning, the ITER experimental reactor is under construction in Saint-Paul-les-Durance, France. Japan is taking on important roles such as the development and production of major pieces of ITER components including divertors and toroidal field coils (TF coils). QST is the ITER Project's agent in Japan and it promotes the procurement of equipment.The divertor is one of the most important components of a tokamak*3 and other magnetic confinement*4 fusion reactors. Divertors play an important role in maintaining the stability of the nuclear fusion reaction and exhausting impurities such as fuel residue and the helium generated by the nuclear fusion reaction in the reactor core plasma.*5 Divertors are the only tokamak devices capable of directly receiving plasma. They are used in a severe environment where they are exposed to heat load and particle load from the plasma. For this reason, special materials such as tungsten are used to make them. Tungsten has a high-melting-point but it is difficult to machine. Moreover, the plasma-facing surfaces are precisely shaped, requiring high-precision machining and assembly technologies to achieve the correct overall shape, inclination, steps and gaps that are accurate to 0.5 mm or less. It is believed that divertors are the hardest piece of the ITER in-vessel components to manufacture.*3 The method, represented by ITER and JT-60SA, retains an ultra-high temperature plasma that is more than 100 million degrees or higher within a strong magnetic field in a vacuum, and nuclear fusion reactions occur within the plasma. See *5 regarding plasma. See *11 for information about JT-60SA.*4 Fusion plasma is at very high temperature and cannot be kept in a conventional container, but it retains positively or negatively charged ions and characteristically becomes entangled in magnetic fields (lines of magnetic force). Using these characteristics, a magnetic confinement fusion reactor forms a basket-like magnetic field to retain plasma.*5 Plasma is one of the four basic states of matter. It is the fourth state next to solid, liquid and gas. When matter is exposed to very high temperatures or a strong electromagnetic field, atoms break down and separate to positively charged ions and negatively charged electrons, and they form plasma.The heat load on divertors reaches a maximum of 20 megawatts per square meter. This is equivalent to the surface heat load that an asteroid probe is exposed to when entering the atmosphere and much more than the surface heat load the space shuttle was subjected to. Outer vertical targets need to have a strong mechanical structure because they are subject to strong electromagnetic forces that can reach an approx. maximum of 16.5 tons. The establishment of technology for making divertors resistant to high heat loads and huge electromagnetic forces is a very important part of increasing the power output of fusion reactors, reducing the size of the reactors or increasing their magnetic fields in the future.Characteristics of the technology for the production of the second prototypeQST leads the manufacturers' material development efforts, regarding them as key technology for enabling divertors to withstand heat load that can be as high as 20 megawatts per square meter. Consequently, the company established methods of producing tungsten monoblocks*6 which do not break even under heat load, and copper alloy cooling pipes which are kept strong by maintaining high thermal conductivity while limiting the coarsening of their crystal grain. To bond these materials together, a brazing*7 technology that is resistant to high heat load has also been developed.*6 This is one of the components of the outer vertical targets that are a combination of tungsten, a metal that is resistant to heat load, and a copper buffer material.*7 A method of bonding metals. The technology uses a metal called a brazing material to bond base materials to each other. In contrast, welding is a method of bonding metals by welding a base material.By combining technologies and experience which are accumulated over many years in the nuclear energy business, Hitachi has developed a defect-free, high-quality welding technology for special materials and a non-destructive technology for inspecting restricted and complex shapes, and repeated demonstration testing has shown that Hitachi has achieved the high-precision machining and assembly technology that is accurate to 0.5 mm or less, a requirement of the ITER Organization. To rationalize production processes and costs, an automatic welding system optimized specially for divertors was introduced for welding thick, high-strength stainless steel. Instead of manual work, a robotic arm with a welding torch attached is combined with a device that controls the position of the object to be welded in synchronization with the movement of the robotic arm, resulting in higher quality welding at low cost.The special materials necessary for outer vertical targets are procured by QST from material manufacturers and are supplied to Hitachi which uses the special materials provided by QST to machine and assemble outer vertical targets in a strictly quality-controlled process. QST maintains and uses a high-temperature helium leak test facility*8 for the in-vessel components of fusion reactors that is the only one of its kind in Japan, and it independently conducts final tests to ensure the quality of the divertors.*8 The test facility uses helium gas to check for leaks with high precision at a high temperature of 250'C which is the environment that divertors will be used in.Initiatives implemented by Hitachi and QST to dateTo date, Hitachi and QST have been developing and manufacturing an ultra-high-voltage power supply system*9 with a voltage of 1 million volts for neutral beam injectors*10 for ITER. Currently, a system is being tested in Italy. Production of the devices to be delivered to France has commenced at Hitachi's factory. To realize fusion energy quickly, efforts are under way in Japan to reinforce neutral beam injectors for JT-60SA,*11 the world's largest superconducting tokamak device built jointly by Japan and Europe in parallel with the ITER Project.*9 The system supplies the power needed to actuate neutral beam injectors.*10 The device for injecting high-energy hydrogen atoms into plasma to heat the plasma. It heats the plasma to an ultra-high temperature of more than 100 million degrees, the temperature at which a nuclear fusion reaction occurs.*11 For information about JT-60SA, see the explanation about the JT-60SA Project on the website of the National Institutes for Quantum Science and Technology.Website about Hitachi's fusion businesshttps://www.hitachi.co.jp/products/energy/nuclear/accelerator/index.htmlAbout Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About LumadaAbout the National Institutes for Quantum Science and TechnologyThe National Institutes for Quantum Science and Technology (QST) was established in April 2016 to promote quantum science and technology in a comprehensive and integrated manner. QST leads the world in 3 fields of research and development. Research on Quantum Technology Basis aims to create high functionality materials and devices utilizing high end laser technology. Research on Quantum Biological science aims to elucidate biological processes based on quantum science and technology. Research on Innovative Diagnosis and Treatment for Cancer and Dementia and other symptoms aims to realize a society of healthy longevity through heavy ion therapy, high precision diagnosis utilizing PET and treatments using targeted isotope therapy. Furthermore, the operation and maintenance of 3GeV-class synchrotron radiation facility “NanoTerasu” will be conducted as a national center of core high radiation medical assistance with public-private partnership leading technical development and human resource development in radiation medicine. Visit us at https://www.qst.go.jp/Contact information for Hitachi, Ltd.Business ContactTaku OyamaProject Management GroupFusion and Accelerators Development CenterGroup Leader Senior EngineerHitachi, Ltd+81-294-55-3420taku.oyama.ke@hitachi.comContact information for National Institutes for Quantum Science and TechnologyBusiness & Media ContactQST International Affairs and Public Relations Section,Department of International Affairs and Public Relations+81-432-06-3026info@qst.go.jp Copyright 2025 JCN Newswire via SeaPRwire.com.

Showcasing a prototype LEO satellite communication terminal (*1) enabling high-speed, high-capacity communication in areas with limited cellular coverageTOKYO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Sharp Corporation (herein after "Sharp") will exhibit at the 2nd SPEXA - International Space Business Expo, held at Tokyo Big Sight (Koto-ku, Tokyo) from Wednesday, July 30 to Friday, August 1. Sharp will showcase a LEO satellite communication terminal under development, leveraging its expertise in compact, lightweight design and communication technologies from smartphone development, along with supporting applications and field trial initiatives.Booth Image - Main Exhibits* LEO Satellite Communication Terminal (Reference Exhibit)Sharp will exhibit the terminal and introduce potential use cases such as real-time data transmission, location sharing, and remote control in areas with limited cellular connectivity, including maritime and mountainous regions. The terminal is also proposed as a solution for business continuity plan (BCP) during disasters. A conceptual ultra-compact model, designed for drone integration, will be presented as part of Sharp's efforts toward next-generation field solutions.* Satellite Operation Application (Reference Exhibit)A dedicated application supports the efficient operation and management of the LEO satellite communication terminal. It allows users to monitor terminal status, nearby obstacles, and satellite positioning. In case of a malfunction, the app provides troubleshooting guidance, streamlining maintenance tasks.* Field TrialsSharp will present field trials conducted using the compact and lightweight LEO satellite communication terminal, installed on vessels and vehicles. Through these tests, Sharp is accelerating development to ensure stable communication under various conditions by evaluating practical performance and identifying technical challenges.*1 A user terminal integrating a LEO satellite communication antenna and modem functions. LEO stands for Low Earth Orbit.- Exhibition LocationTokyo Big Sight, South Exhibition Hall – Satellite Data & Space Utilization Area, Booth No.S6-34- LEO Satellite Communication User Terminal Images *2 A method that enhances system reliability by duplicating the system and keeping one in standby. In the field of communications, it refers to a system that enables bidirectional communication.*3 A type of bidirectional communication in which transmission and reception are performed alternately.*4 The LEO satellite communication terminal supports dual carrier operation.This development has been funded by the National Institute of Information and Communications Technology (NICT) (JP012368G50501). Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, “KYORIN”) announced today that Eisai (Thailand) Marketing Co., Ltd. (“Eisai Thailand”), a subsidiary of Eisai, has launched overactive bladder treatment Beova® Tablets (generic name vibegron) in Thailand.In 2021, Eisai acquired exclusive development and marketing rights from KYORIN for the agent in ASEAN member states Thailand, the Philippines, Malaysia, and Brunei. Eisai Thailand submitted an application for marketing authorization in Thailand in March 2023, and received approval in June 2024. This launch is the first within Eisai’s licensed region. In addition to the release in Thailand, approval has also been obtained in the Philippines and Malaysia, with preparations underway for market entry.Overactive bladder (OAB) is a urological condition with trouble in pooling urine in the bladder. It's predominant symptom is an urge to urinate, which is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence. One of the major problems of OAB is the fact that patients refrain from leaving the house due to anxiety about going to the bathroom, cannot get enough sleep at night, or face limitations in their daily activities, which could lead to significantly-reduced quality of life.Appropriate treatment is necessary for OAB, which increases with age but has also been reported to becaused by brain or spinal cord disorders such as cerebrovascular diseases (cerebral hemorrhage and cerebral infarction), Parkinson's disease, and benign prostatic hyperplasia.1 The prevalence of OAB in Thailand is reported to be 15.8%.2This agent is a selective B3-adrenergic receptor agonist administered once daily, acting selectively on B3 receptors in the bladder, relaxing the bladder to enhance urine collection, and consequently improving the symptoms of urgency, urinary frequency and urge urinary incontinence associated with OAB.In September 2009, KYORIN and Eisai signed a license agreement for the development and marketing in Asia of Uritos® Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, discovered and developed by KYORIN, and as of today Eisai sells Uritos in Thailand, the Philippines, Indonesia, Cambodia, Vietnam, Laos and Myanmar. In addition to Uritos, Eisai will provide patients with new treatment options for OAB through the launch of Beova in Thailand and make further contributions to improving the quality of life and increasing benefits to patients with OAB in Asia.1. About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target(3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com, and connect with us on X, LinkedIn and Facebook. 2. About KYORIN Pharmaceutical Co., Ltd.KYORIN operates under the corporate philosophy, "KYORIN continues to fulfil it's mission of cherishing life and benefiting society by contributing to better health." Based on this principle, we aim to continuously provide high-valuenew drugs that meet medical needs, striving to become a company that contributes broadly to people's health. In drug discovery, we focus our research efforts on the therapeutic areas of pain and autoimmune disorders etc., working to create innovative new drugs that meet significant medical needs. In sales, we implement a Franchise Customer (FC) strategy, concentrating our resources on specialized areas, respiratory, otolaryngology, and urology.For more information on KYORIN Pharmaceutical Co., Ltd., please visit https://www.kyorin-pharm.co.jp/en/.3. About vibegronVibegron was discovered by Merck & Co., Rahway, N.J., U.S.A. (known as MSD outside of the United States and Canada) as a once-daily oral treatment for overactive bladder (OAB), which acts selectively on the bladder's B3-adrenergic receptor agonists. Vibegron selectively acts on B3 receptors in the bladder and increases bladder capacity by enhancing the bladder-relaxing effect of noradrenaline during the urinary storage phase, resulting in the improvement of incontinence symptoms of urinary urgency, frequent urination and urge urinary incontinence with OAB. KYORIN has obtained exclusive rights for developing, manufacturing and marketing of this drug in Japan (July 2014) and Asia* (April2017) from Merck & Co., Inc., Rahway, N.J., U.S.A.In Eisai’s licensed territories (Thailand, the Philippines, Malaysia and Brunei), in addition to it's new launch in Thailand, approvals have been obtained in the Philippines and Malaysia, with preparations underway for market entry. In Japan, KYORIN and Kissei have jointly developed the agent locally under a co-development and co-marketing agreement entered into as of March 2016. Since November 2018, the two companies have been jointly marketing it under the product name of “Beova® Tablets 50mg”.*South Korea, Taiwan, Hong Kong, and 10 member states of ASEAN1 Clinical Guidelines for Overactive Bladder Syndrome 3rd Edition (Japanese only)2 ICS2024 Abstract 554 https://www.ics.org/2024/abstract/554Media InquiriesEisai Co., Ltd.Public Relations DepartmentTEL: +81-(0)3-3817-5120KYORIN Pharmaceutical Co., Ltd.Corporate PlanningTEL: +81-(0)3-6374-9702 Copyright 2025 JCN Newswire via SeaPRwire.com.

SAN DIEGO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, announced today that its San Diego laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This significant milestone enables Crown Bioscience to deliver clinical-grade testing, further strengthening its support for clients' clinical and translational drug development efforts.CLIA, regulated by the Centers for Medicare and Medicaid Services (CMS), sets rigorous federal standards for accuracy, reliability, and quality laboratory operations. With this designation, Crown Bioscience’s San Diego facility affirms full compliance, providing clients with increased confidence in the biomarker data used for clinical decision-making and regulatory submissions."Achieving this marks a crucial step in our commitment to delivering high-quality, compliant laboratory services," said Julie Mayer, Vice President, Global Biomarker Platform at Crown Bioscience. "This enables us to expand our offerings by leveraging CLIA certification to support our partners in accelerating their clinical development and regulatory approval timelines."As a CLIA-certified laboratory, Crown Bioscience is now equipped to conduct clinical testing on human specimens, a key component of advancing oncology research and personalized medicine. This designation strengthens the company’s position as a trusted partner capable of meeting specialized project needs throughout all stages of drug development.For more information about Crown Bioscience’s certifications and accreditations, please visit the company’s website.About Crown BioscienceCrown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit www.crownbio.com.Media Inquiries:Crown BioscienceSarah Martin-Tyrrellpr@crownbio.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 22, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced the termination of its engine business operation at Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Co., Ltd. (hereinafter, SAME) in China and has terminated the joint venture partnership.Established in August 1997, SAME began engine production in 1998 and has played a key role in China’s expanding automotive market by supplying engines not only to Mitsubishi-branded vehicle manufacturers, but also to numerous Chinese automakers. However, in response to the rapid transformation of China’s automotive industry, Mitsubishi Motors has reassessed its strategy in the region and has decided to terminate its participation in the joint venture.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society. For more information on Mitsubishi Motors, please visit the company's website athttps://www.mitsubishi-motors.com/en/ Copyright 2025 JCN Newswire via SeaPRwire.com.

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab longterm data, an immunoassay for measuring amyloid-B protofibrils in cerebrospinal fluid, and asubcutaneousl form of lecanemab for continued treatment of ADAD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque depositionTOKYO, July 22, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. Eisai will present 21 oral presentations, 24 posters, three (3) symposia and two (2)lecanemab product theaters.Key Oral Lecanemab Presentations• Four-year Data: On Wednesday July 30 (8:00 – 8:45 AM EDT), as part of the “Developing Topics Session: Innovative Therapeutic Approaches”, initial four-year findings will be presented on lecanemab from the Phase III Clarity AD Open-Label Extension in Early Alzheimer's Disease trial.• Subcutaneous Maintenance Dosing: A Featured Research Session on Wednesday, July 30 (9:00 –10:30 AM EDT) will include data on the potential of a new and convenient option for ongoing lecanemab treatment, the subcutaneous formulation for maintenance dosing.• Real World Case Studies: A Developing Topics Session on Sunday, July 27 (9:00 – 10:30 AM EDT) will include data on real-world case studies and patient pathway learnings from diverse U.S. clinical settings two years post-approval of lecanemab.Key Lecanemab Poster Presentation• A Poster Presentation on Monday, July 28 (viewing available from 7:30 AM – 4:15 PM EDT) will share findings on cerebrospinal fluid (CSF) samples collected from the Clarity AD trial and analyzed using the novel, sensitive immunoassay developed to measure amyloid-B protofibrils in CSF.Key Oral E2814 Presentation• A Featured Research Session on Wednesday, July 30 (4:15 PM – 5:45 PM EDT) will include findings from “Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer’s Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial.”“The data presented at AAIC 2025 will highlight long-term findings from lecanemab’s open-label extension trial, real-world lecanemab case studies as well as results on a subcutaneous formulation and dosing regimen that may offer patients more flexibility to continue treatment to fight Alzhierm’s disease,” said LynnD. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. “Eisai will also share preliminary results from the DIAN-TU-001 NexGen Trial, exploring etalanetug with background lecanemab therapy to slow or prevent the progression of Alzhierm’s disease. As we gain more experience using dual-acting lecanemab in different clinical settings and continue to explore new avenues to improve the diagnosis and treatment of Alzhierm’s disease, we are hopeful about the future. We remain committed to patients and their loved ones who are impacted by this progressive, relentless disease, caused by a continuous underlying neurotoxic process that begins before and continues after plaque is removed from the brain.”For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202548pdf.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 22, 2025 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station, an anime exhibition center that utilizes Japanese anime content with a strong fan base around the world, serves as a facility enjoyed by children and adults alike. Since opening, it has welcomed 190,624 visitors from both Japan and overseas (as of July 6, 2025), and regularly hosts special exhibitions featuring popular anime series.We are pleased to announce that the TV Anime “SPYxFAMILY” Special Exhibition will be held from August 16 to November 9, 2025, featuring the series that has gained popularity not only in Japan, but worldwide.The special exhibition will look back on various memorable scenes while exploring the appeal of each character from the series. Visitors can enjoy an AR experience where character dialogue appears when they hold up their smartphones, photo spots for taking pictures while being immersed in the world of the series, and other features that allow them to experience the characters’ appeal firsthand.We invite you to visit Anime Tokyo Station and fully enjoy the world of TV anime “SPYxFAMILY” and the appeal of its characters.TV Anime “SPYxFAMILY” Special ExhibitionExhibition OverviewIn addition to scene cuts revisiting memorable moments and photo spots, interactive exhibits will be featured. This special exhibition allows visitors to experience the world of the SPYxFAMILY anime and the appeal of the characters appearing in the series.Main Exhibition ContentsExhibitsScene panels revisiting memorable momentsPhoto spots for taking pictures while enjoying the world of the seriesLife-size character panelsExperience CornerAR experience featuring dialogue from exhibited characters *Further details regarding exhibition contents will be announced on the official Anime Tokyo Station website once confirmed.PeriodAugust 16 – November 9, 2025What is SPYxFAMILY?In a world of fierce intelligence warfare, the spy “Twilight” receives a mission: create a fake family and attend an elite school’s social gathering to make contact with the target and prevent war with a neighboring country. Twilight assumes the identity of ordinary citizen Loid Forger and assembles a family—but his daughter Anya can read minds, and his wife Yor is a deadly assassin. This hit spy comedy follows a family of secrets striving for world peace.Tatsuya Endo’s original manga began serialization in Shonen Jump+ in March 2019, winning multiple manga awards and surpassing 38 million copies with 15 volumes (as of March 2025).When Season 1 premiered in April 2022, to meet the high expectations of the manga’s fanbase, an unprecedented collaboration was formed between WIT STUDIO and CloverWorks. The production brought together industry-leading talent including director Kazuhiro Furuhashi, as well as popular voice actors Takuya Eguchi, Atsumi Tanezaki, Saori Hayami, and Kenichiro Matsuda, with theme songs by OFFICIAL HIGE DANDISM and Gen Hoshino in the first run of the series, followed by BUMP OF CHICKEN and yama in the second, establishing it as 2022’s breakout anime hit.Season 2 aired from October 2023, bringing the fan-favorite Luxury Cruise Arc from the original work to life on an even grander scale. Ado’s opening theme “Kura Kura” and Vaundy’s ending theme “Todome no Ichigeki (feat. Cory Wong)” became instant sensations.The franchise’s first film, SPYxFAMILY CODE: White, premiered December 22, 2023, with Tatsuya Endo providing the original work, supervision, and character designs. Season 1 director Kazuhiro Furuhashi served as animation advisor, while Season 1 assistant director Takashi Katagiri took the helm. Ichiro Okouchi crafted an entirely original story for the screenplay. Riding the wave of popularity enjoyed by “MIXED NUTS,” OFFICIAL HIGE DANDISM delivered the theme song “SOULSOUP,” with the opening day surprise announcement that Gen Hoshino would perform the ending theme “Why”—reuniting the beloved Season 1 combination to tremendous fan enthusiasm. The film became a blockbuster success, earning 6.26 billion yen and drawing over 4.64 million viewers. With Season 3 set to begin in October 2025 in Japan, anticipation continues to build.Venue Overview- Name: Anime Tokyo Station (also known as "Anime Tokyo")- Location: Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro Station- Hours: 11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m.)- Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.- Admission fee: Free- Website: https://animetokyo.jp/en/- SNS:X | https://x.com/animetokyo_info (@animetokyo_info)Instagram | https://www.instagram.com/animetokyostation/ (@animetokyostation)YouTube | https://www.youtube.com/channel/UCSJOjGJE5Yiqw3PZ97AVdJwInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/files/20250722.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.

SINGAPORE, JULY 21, 2025 - (ACN Newswire via SeaPRwire.com) - AGI research company Sapient Intelligence today announced the open-source release of its Hierarchical Reasoning Model (HRM), a brain-inspired architecture that leverages hierarchical structure and multi-timescale processing to achieve substantial computational depth without sacrificing training stability or efficiency. Trained on just 1000 examples without pre-training, with only 27 million parameters, HRM successfully tackles reasoning challenges that continue to frustrate today's large language models (LLMs).Beyond LLM Reasoning LimitsCurrent LLMs depend heavily on Chain-of-Thought prompting, an approach that often suffers from brittle task decomposition, immense training data demands and high latency. Inspired by the hierarchical and multi-timescale processing in the human brain, HRM overcomes these constraints by embracing three fundamental principles observed in cortical computation: hierarchical processing, temporal separation, and recurrent connectivity. Composed of a high-level module performing slow, abstract planning and a low-level module executing rapid, detailed computations, HRM is capable of alternating dynamically between automatic thinking ("System 1") and deliberate reasoning ("System 2") in a single forward pass."AGI is really about giving machines human-level, and eventually beyond-human, intelligence. CoT lets the models imitate human reasoning by playing the odds, and it's only a workaround. At Sapient, we're starting from scratch with a brain-inspired architecture, because nature has already spent billions of years perfecting it. Our model actually thinks and reasons like a person, not just crunches probabilities to ace benchmarks. We believe it will reach, then surpass, human intelligence, and that's when the AGI conversation gets real," said Guan Wang, founder and CEO of Sapient Intelligence.Inspired by the brain, HRM has two recurrent networks operating at different timescales to collaboratively solve tasks [Sapient 2025.07.21]Benchmark BreakthroughsDespite its compact scale of 27 million parameters and using only 1000 input-output examples,all without any pre-training or Chain-of-Thought supervision, HRM learns to solve problems thateven the most advanced LLMs struggle with. In the Abstraction and Reasoning Corpus (ARC) AGI Challenge, a widely accepted benchmark of inductive reasoning, HRM archives aperformance of 5% on ARC-AGI-2, significantly outperforming OpenAI o3-mini-high, DeepSeekR1, and Claude 3.7 8K, all of which rely on far larger sizes and context lengths. In complex Sudoku puzzles and optimal pathfinding in 30x30 mazes, where state-of-the-art CoT methods completely fail, HRM delivers near-perfect accuracy.With only about 1000 training examples, the HRM (~27M parameters) surpasses state-of-the-art CoT models on ARC-AGI, Sudoku-Extreme, and Maze-Hard [Sapient 2025.07.21]The Sapient Intelligence team is already running new experiments and expect to publish even stronger ARC-AGI scores soon.Real-World ImpactHRM data efficiency and reasoning accuracy open new opportunities in fields where large datasets are scarce yet accuracy is critical. In healthcare, Sapient is partnering with leading medical research institutions to deploy HRM to support complex diagnostics, particularly rare-disease cases where data signals are sparse, subtle, and demand deep reasoning. In climate forecasting, HRM raises subseasonal-to-seasonal (S2S) forecasting accuracy to 97 %, a leap that translates directly into social and economic value. In robotics, HRM's low-latency, lightweight architecture serves as an on-device "decision brain," enabling next-generation robots to perceive and act in real time within dynamic environments.Path ForwardSapient Intelligence believes that HRM presents a viable alternative to the currently dominant CoT reasoning models. It offers a practical path toward universally capable reasoning systems that rely on architecture, not scale, to push the frontier of AI and, ultimately, close the gap between today's models and true artificial general intelligence.AvailabilityThe source code is available on GitHub at https://github.com/sapientinc/HRM.About Sapient IntelligenceSapient Intelligence is a global AGI research company headquartered in Singapore, with research centers in San Francisco and Beijing, building next-generation AI models for complex reasoning. Our mission is to reach artificial general intelligence by developing a radically new architecture that integrates reinforcement learning, evolutionary algorithms, and neuroscience research to push beyond the limits of today's LLMs.In July 2025, we introduced the Sapient Hierarchical Reasoning Model (HRM), a hierarchical, brain-inspired model that achieves deep reasoning with minimal data. With just 27 million parameters and approximately 1,000 training examples, without pre-training, Sapient HRM achieves near-perfect accuracy on Sudoku Extreme, Maze Hard, and other high-difficulty math tasks and outperforms current models that are significantly larger on the ARC-AGI. Early pilot applications will include healthcare, robot control, and climate forecasting.Our fast-growing team includes alumni of Google DeepMind, DeepSeek, Anthropic, and xAI, alongside researchers from Tsinghua University, Peking University, UC Berkeley, the University of Cambridge, and the University of Alberta, working together to close the gap between today's language models and true general intelligence.For more information, visit www.sapient.inc.Media Contact:genli@sapient.inc press@sapient.incThis press release is issued through EmailWire (www.emailwire.com) - the global newswire service that provides effective, local, statewide, national and international press release distribution with guaranteed results. Copyright 2025 JCN Newswire via SeaPRwire.com.